Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy

Table 1 Associations of clinical variables with OS in BRCA (total N = 979)

		N	%	HR (95%CI)	P
Radiotherapy^a	No	421	43.00	1.000
	Yes	558	57.00	0.520(0.340, 0.795)	0.003
Chemotherapy^a	No	140	14.42	1.000
	Yes	831	85.58	0.382(0.230, 0.635)	< 0.001
Age^a	< 60	526	53.78	1.000
	≥ 60	452	46.22	2.005(1.339, 3.004)	< 0.001
Race	White	680	74.97	1.000
	Others	227	25.03	1.336(0.844, 2.116)	0.217
History of cancer	No	915	93.56	1.000
	Yes	63	6.44	1.621(0.746,3.521)	0.223
Surgery type^a	Mastectomy	465	50.05	1.000
	Lumpectomy	235	25.30	0.928(0.544, 1.581)	0.782
	Other	229	24.65	0.596(0.359, 0.989)	0.045
Margin status^a	Negative	841	89.09	1.000
	Positive/close	103	10.91	1.750(1.063, 2.882)	0.028
Histology	IDC	697	71.20	1.000
	ILC	191	19.51	0.950(0.551, 1.639)	0.854
	Other	91	9.30	1.614(0.898, 2.900)	0.140
ER status	Negative	215	22.95	1.000
	Positive	722	77.05	1.118(0.585, 2.137)	0.736
PR status^a	Negative	308	32.98	1.000
	Positive	626	67.02	0.563(0.375, 0.846)	0.006
HER2	Negative	496	60.41	1.000
	Positive	142	17.30	1.172(0.682, 2.013)	0.567
	Indeterminate	183	22.29	0.904(0.572, 1.429)	0.667
Menopausal status	Pre/peri	286	30.75	1.000
	Post	644	69.25	1.487(0.868,2.547)	0.148
T Stage	T1/T2	822	84.22	1.000
	T3/T4	154	15.78	0.971(0.565, 1.668)	0.914
N Stage^a	N0	466	48.49	1.000
	N1/N2/N3	495	51.51	1.851(1.096, 3.127)	0.021
M Stage^a	M0	961	98.16	1.000
	M1	18	1.84	1.998(1.031, 3.869)	0.040
Pathological stage^a	I/II	717	74.84	1.000
	III/IV	241	25.16	2.147(1.269, 3.635)	0.004

IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; TNM, tumor-node-metastasis stage
^aClinical variables that were left after fast backward multivariate COX regression

ISSN: 1748-717X